Phio Pharmaceuticals is a Finalist for the Technology Disruptor of the Year Award

Dec 10, 2024 | Press Releases

Award is being presented during Advanced Therapies Week 2025 in DallasMarlborough, Massachusetts–(Newsfile Corp. – December 10, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO),) is a clinical-stage biotechnology company developing therapeutics that...

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Dec 3, 2024 | Press Releases

Registration Link for Presentation and live Q&A to take place, Tuesday, December 10, 2024 at 12:00 pm ESTMarlborough, Massachusetts–(Newsfile Corp. – December 3, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology...

Phio Pharmaceuticals Announces Completion of Enrollment in Second Cohort in Phase 1b Dose-Escalating Clinical Study

Nov 19, 2024 | Press Releases

–Six sites across the U.S. are now engaged in Phase1b study Marlborough, Massachusetts–(Newsfile Corp. – November 19, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company exploring new pathways towards a...

Phio Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 14, 2024 | Press Releases

Marlborough, Massachusetts–(Newsfile Corp. – November 14, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company exploring new pathways towards a cancer-free future by using its INTASYL® siRNA gene silencing...

Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Nov 7, 2024 | Press Releases

Presenting new clinical data from Phio’s on-going Phase 1b trialMarlborough, Massachusetts–(Newsfile Corp. – November 7, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company creating new pathways towards a...